Apellis Pharmaceuticals, Inc. APLS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

48/100

1/7 Pass

SharesGrow Intrinsic Value

Ha habido 50 transacciones internas recientes registradas para Apellis Pharmaceuticals, Inc. (APLS), incluyendo 17 compras y 30 ventas. El total de compras internas fue valorado en $2.58M y el total de ventas internas en $3.11M.

Internos destacados con actividad reciente incluyen Biogen Inc., Francois Cedric, Dolsten Mikael. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.

Operaciones de Insiders — APLS

Fecha	Nombre	Cargo	Tipo de Transacción	Acciones	Precio Promedio	Valor	Acciones en Propiedad
2026-03-31	Biogen Inc.	Other: See Footnotes	Desconocido	-	-	-	-
2026-03-11	Francois Cedric	Chief Executive Officer	Donación (Recibida)	64,869	-	-	372,815
2026-03-02	Dolsten Mikael	Director	Desconocido	-	-	-	-
2026-02-27	Dolsten Mikael	Director	Concesión de RSU	14,312	-	-	14,312
2026-02-11	Delong Mark Jeffrey	Chief Business & Strat Officer	Venta Informativa	368	$22.15	$8.15K	114,591
2026-02-03	Francois Cedric	Chief Executive Officer	Ejercicio de Opciones (Venta)	8,840	$3.76	$33.24K	-
2026-01-28	Watson David O.	General Counsel	Concesión de RSU	55,986	-	-	144,517
2026-01-28	Deschatelets Pascal	Chief Scientific Officer	Concesión de RSU	25,840	-	-	1,177,222
2026-01-28	Francois Cedric	Chief Executive Officer	Concesión de RSU	195,952	-	-	481,997
2026-01-28	Sullivan Timothy Eugene	Chief Financial Officer	Concesión de RSU	58,140	-	-	152,041
2026-01-28	Nicholson Nur	Chief Technical Officer	Concesión de RSU	45,220	-	-	116,338
2026-01-28	Chopas James George	VP/chief Accounting Officer	Concesión de RSU	16,150	-	-	65,955
2026-01-28	Delong Mark Jeffrey	Chief Business & Strat Officer	Concesión de RSU	36,606	-	-	114,959
2026-01-28	Boucher Kelley	Chief People Officer	Concesión de RSU	30,146	-	-	127,804
2026-01-28	Meltzer Leslie	Chief Research and Development	Concesión de RSU	45,220	-	-	107,024
2026-01-22	Watson David O.	General Counsel	Venta Informativa	7,832	$21.77	$170.47K	88,531
2026-01-22	Deschatelets Pascal	Chief Scientific Officer	Venta Informativa	5,928	$21.77	$129.03K	1,151,382
2026-01-22	Francois Cedric	Chief Executive Officer	Venta Informativa	27,192	$21.77	$591.84K	286,045
2026-01-22	Sullivan Timothy Eugene	Chief Financial Officer	Venta Informativa	10,287	$21.77	$223.9K	93,901
2026-01-22	Nicholson Nur	Chief Technical Officer	Venta Informativa	7,725	$21.77	$168.14K	71,118
2026-01-22	Chopas James George	VP/chief Accounting Officer	Venta Informativa	2,064	$21.77	$44.92K	49,805
2026-01-22	Delong Mark Jeffrey	Chief Business & Strat Officer	Venta Informativa	3,371	$21.77	$73.37K	78,353
2026-01-22	Baumal Caroline	Chief Medical Officer	Venta Informativa	2,797	$21.77	$60.88K	86,527
2026-01-20	Watson David O.	General Counsel	Venta Informativa	2,475	$19.79	$48.99K	96,363
2026-01-20	Deschatelets Pascal	Chief Scientific Officer	Venta Informativa	909	$19.79	$17.99K	1,157,310
2026-01-20	Francois Cedric	Chief Executive Officer	Venta Informativa	8,182	$19.79	$161.95K	313,237
2026-01-20	Sullivan Timothy Eugene	Chief Financial Officer	Venta Informativa	2,892	$19.79	$57.24K	104,188
2026-01-20	Nicholson Nur	Chief Technical Officer	Venta Informativa	2,203	$19.79	$43.6K	78,843
2026-01-20	Chopas James George	VP/chief Accounting Officer	Venta Informativa	726	$19.79	$14.37K	51,869
2026-01-20	Delong Mark Jeffrey	Chief Business & Strat Officer	Venta Informativa	1,334	$19.79	$26.4K	81,724
2026-01-20	Baumal Caroline	Chief Medical Officer	Venta Informativa	1,882	$19.79	$37.25K	89,324
2026-01-13	Watson David O.	General Counsel	Venta Informativa	5,780	$22.19	$128.24K	98,838
2026-01-13	Deschatelets Pascal	Chief Scientific Officer	Venta Informativa	2,277	$22.19	$50.52K	1,158,219
2026-01-13	Francois Cedric	Chief Executive Officer	Venta Informativa	10,186	$22.19	$226K	321,419
2026-01-13	Sullivan Timothy Eugene	Chief Financial Officer	Venta Informativa	3,856	$22.19	$85.55K	107,080
2026-01-13	Nicholson Nur	Chief Technical Officer	Venta Informativa	2,618	$22.19	$58.09K	81,046
2026-01-13	Chopas James George	VP/chief Accounting Officer	Venta Informativa	873	$22.19	$19.37K	52,595
2026-01-13	Delong Mark Jeffrey	Chief Business & Strat Officer	Venta Informativa	1,780	$22.19	$39.49K	83,058
2026-01-07	Watson David O.	General Counsel	Ejercicio de Opciones (Venta)	888	$14.95	$13.28K	14,000
2026-01-05	Baumal Caroline	Chief Medical Officer	Venta Informativa	3,020	$25.53	$77.1K	91,206
2026-01-01	Wheeler Craig A	Director	Concesión de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	Machiels Alec	Director	Concesión de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	Chan Gerald	Director	Concesión de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	O'brien Stephanie Monaghan	Director	Concesión de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	Dunlop A. Sinclair	Director	Concesión de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	Fonteyne Paul R.	Director	Concesión de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	Walbert Keli	Director	Concesión de RSU	14,684	$25.12	$368.86K	14,684
2025-12-16	Watson David O.	General Counsel	Venta Informativa	5,000	$24.49	$122.45K	103,730
2025-11-17	Watson David O.	General Counsel	Venta Informativa	5,000	$20.06	$100.3K	108,730
2025-10-21	Sullivan Timothy Eugene	Chief Financial Officer	Venta Informativa	10,000	$28.03	$280.3K	110,936

■ Informativa — transacción en mercado abierto (más significativa) ■ No informativa (compra) — premio, ejercicio de opción, conversión ■ No informativa (venta) — retención fiscal, venta de adjudicación ■ Neutral — regalo, fideicomiso, vencimiento